Skip to main content
SpringerLink
Log in

The use of once-weekly epoetin-α has no effect on health-related quality of life (HRQOL) in children with cancer,*

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR.Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. Journal of Clinical Oncology 24: 3583-3589, No. 22, 1 Aug 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The use of once-weekly epoetin-α has no effect on health-related quality of life (HRQOL) in children with cancer,*. Pharmacoecon. Outcomes News 511, 9 (2006). https://doi.org/10.2165/00151234-200605110-00022

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605110-00022

Keywords

Search

Navigation